Enoxaparin
(Synonyms: PK 10169; Enoxaparin sodium; Lovenox) 目录号 : GC68034Enoxaparin (PK 10169) 是一种低分子肝素 (LMWH) 衍生物。Enoxaparin 通过抗凝血酶 III 发挥其抗凝血 (anticoagulant) 活性，抗凝血酶 III 是一种内源性 Xa 因子和凝血酶 IIa (thrombin IIa) 的抑制剂。Enoxaparin 可通过抗氧化 (antioxidant) 和抗炎 (anti-inflammatory) 作用保护大鼠海马区免受 TBI 损伤。Enoxaparin 可用于深静脉血栓形成 (DVT)、肺栓塞、外伤性脑损伤 (TBI) 和 COVID-19 的研究。
Cas No.:679809-58-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of Factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19[1][2][3].
Enoxaparin (0-70 µg/mL, 90 min) enhances AAT (alpha-1-antitrypsin) inhibition of both TMPRSS2 (Transmembrane Protease 2) activity and infection of hAEc (human airway epithelial cells) with HCoV-229E[1].
Cell Viability Assay[1]
| Cell Line: | HEK293T TMPRSS2 cells, hAEc |
| Concentration: | 0, 8.8, 35, 70 µg/mL |
| Incubation Time: | 90 min |
| Result: | Significantly inhibited TMPRSS2 activity at the 90 min incubation period at 35 and 70 µg/mL, enhanced AAT inhibition of TMPRSS2 activity, and augmented AAT inhibition of HCoV-229E infection of hAEc. |
Enoxaparin (1 mg/kg; SC; once every 6 h for 8 times) reduces oxidative damage, inflammation and astrocytosis following TBI (traumatic brain injury) in the rat[2].
| Animal Model: | Adult male Wistar rats (350-450 g, TBI-treated)[2] |
| Dosage: | 0 mg/kg, 1 mg/kg |
| Administration: | SC, once every 6 h, starting at 1 h, and finishing at 43 h after the TBI induction. |
| Result: | Significantly decreased the hippocampal TBARS and oxidized protein levels, COX-2 overexpression and reactive gliosis, but it did not influence the SOD and GSH-Px activities, pro-IL-1β and active caspase-3 overexpressions as well as neurodegeneration following TBI. Reduce oxidative damage, inflammation and astrocytosis following TBI in the rat. |
[1]. Bai X, et al. Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19. Sci Rep. 2022 Mar 25;12(1):5207.
[2]. ?upan ?, et al. Effects of enoxaparin in the rat hippocampus following traumatic brain injury. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1846-56.
[3]. Lee S, Gibson CM. Enoxaparin in acute coronary syndromes. Expert Rev Cardiovasc Ther. 2007 May;5(3):387-99.
| Cas No. | 679809-58-6 | SDF | Download SDF |
| 别名 | PK 10169; Enoxaparin sodium; Lovenox | ||
| 分子式 | 分子量 | ||
| 溶解度 | H2O : ≥ 100 mg/mL | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet